Do analysts rate BGM or RVPH?

Reviva Pharmaceuticals has a consensus target price of $53.33, indicating a potential upside of 10,357.52%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Reviva Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has preferable valuation and earnings, BGM or RVPH?

Reviva Pharmaceuticals has lower revenue, but higher earnings than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $37.92M 3.11 -$19.94M N/A N/A Reviva Pharmaceuticals N/A N/A -$19.86M -$1.85 N/A

Is BGM or RVPH more profitable?

BGM Group's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Reviva Pharmaceuticals N/A -391.58% -119.08%

Does the media favor BGM or RVPH?

In the previous week, BGM Group had 3 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 5 mentions for BGM Group and 2 mentions for Reviva Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 0.00 beat BGM Group's score of -0.33 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BGM Group 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Reviva Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, RVPH or VIRI?

Virios Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Reviva Pharmaceuticals N/A N/A -$19.86M -$1.85 N/A Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A

Is RVPH or VIRI more profitable?

Virios Therapeutics' return on equity of -130.33% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Reviva Pharmaceuticals N/A -391.58% -119.08% Virios Therapeutics N/A -130.33% -115.00%

Do analysts recommend PLRZ or RVPH?

Reviva Pharmaceuticals has a consensus price target of $53.33, indicating a potential upside of 10,357.52%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Reviva Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has higher valuation and earnings, PLRZ or RVPH?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Reviva Pharmaceuticals N/A N/A -$19.86M -$1.85 N/A

Is PLRZ or RVPH more profitable?

Polyrizon's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A Reviva Pharmaceuticals N/A -391.58% -119.08%

Does the media favor PLRZ or RVPH?

In the previous week, Polyrizon had 3 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 5 mentions for Polyrizon and 2 mentions for Reviva Pharmaceuticals. Polyrizon's average media sentiment score of 0.82 beat Reviva Pharmaceuticals' score of 0.00 indicating that Polyrizon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polyrizon 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Reviva Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, QNTM or RVPH?

Quantum Biopharma is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quantum Biopharma N/A N/A -$26.17M -$5.49 N/A Reviva Pharmaceuticals N/A N/A -$19.86M -$1.85 N/A

Is QNTM or RVPH more profitable?

Reviva Pharmaceuticals' return on equity of -391.58% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -582.23% -184.20% Reviva Pharmaceuticals N/A -391.58% -119.08%

Does the media prefer QNTM or RVPH?

In the previous week, Reviva Pharmaceuticals had 1 more articles in the media than Quantum Biopharma. MarketBeat recorded 2 mentions for Reviva Pharmaceuticals and 1 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.00 equaled Reviva Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Reviva Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RVPH or AYTU?

In the previous week, Aytu BioPharma had 8 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 10 mentions for Aytu BioPharma and 2 mentions for Reviva Pharmaceuticals. Aytu BioPharma's average media sentiment score of 0.77 beat Reviva Pharmaceuticals' score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Reviva Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aytu BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Reviva Pharmaceuticals (RVPH) Competitors

$0.51 +0.01 (+2.00%)

As of 03:40 PM Eastern

Compare

RVPH vs. BGM, VIRI, PLRZ, QNTM, and AYTU

Should you buy Reviva Pharmaceuticals stock or one of its competitors? Reviva Pharmaceuticals's main competitors and comparable companies include BGM Group (BGM), Virios Therapeutics (VIRI), Polyrizon (PLRZ), Quantum Biopharma (QNTM), and Aytu BioPharma (AYTU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Reviva Pharmaceuticals compare to BGM Group?

BGM Group (NASDAQ:BGM) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

In the previous week, BGM Group had 3 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 5 mentions for BGM Group and 2 mentions for Reviva Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 0.00 beat BGM Group's score of -0.33 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BGM Group	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Reviva Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Reviva Pharmaceuticals has lower revenue, but higher earnings than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$37.92M	3.11	-$19.94M	N/A	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$1.85	N/A

Reviva Pharmaceuticals has a consensus target price of $53.33, indicating a potential upside of 10,357.52%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 58.7% of BGM Group shares are held by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

BGM Group has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market.

BGM Group's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Summary

BGM Group and Reviva Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Virios Therapeutics?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Virios Therapeutics' return on equity of -130.33% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
Virios Therapeutics	N/A	-130.33%	-115.00%

In the previous week, Reviva Pharmaceuticals had 2 more articles in the media than Virios Therapeutics. MarketBeat recorded 2 mentions for Reviva Pharmaceuticals and 0 mentions for Virios Therapeutics. Reviva Pharmaceuticals' average media sentiment score of 0.00 equaled Virios Therapeutics'average media sentiment score.

Company	Overall Sentiment
Reviva Pharmaceuticals	Neutral
Virios Therapeutics	Neutral

Reviva Pharmaceuticals presently has a consensus price target of $53.33, indicating a potential upside of 10,357.52%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Reviva Pharmaceuticals is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Reviva Pharmaceuticals has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market.

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Virios Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$1.85	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

Summary

Reviva Pharmaceuticals and Virios Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Polyrizon's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

In the previous week, Polyrizon had 3 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 5 mentions for Polyrizon and 2 mentions for Reviva Pharmaceuticals. Polyrizon's average media sentiment score of 0.82 beat Reviva Pharmaceuticals' score of 0.00 indicating that Polyrizon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polyrizon	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Reviva Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$1.85	N/A

Reviva Pharmaceuticals has a consensus price target of $53.33, indicating a potential upside of 10,357.52%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Polyrizon has a beta of -1.2, indicating that its share price is 220% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Reviva Pharmaceuticals beats Polyrizon on 6 of the 11 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Quantum Biopharma?

Quantum Biopharma (NASDAQ:QNTM) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Quantum Biopharma has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market.

1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by company insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Reviva Pharmaceuticals' return on equity of -391.58% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-582.23%	-184.20%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Quantum Biopharma presently has a consensus target price of $8.00, suggesting a potential upside of 144.65%. Reviva Pharmaceuticals has a consensus target price of $53.33, suggesting a potential upside of 10,357.52%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Reviva Pharmaceuticals had 1 more articles in the media than Quantum Biopharma. MarketBeat recorded 2 mentions for Reviva Pharmaceuticals and 1 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.00 equaled Reviva Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Reviva Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quantum Biopharma is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$1.85	N/A

Summary

Reviva Pharmaceuticals beats Quantum Biopharma on 12 of the 12 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Aytu BioPharma?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Aytu BioPharma has higher revenue and earnings than Reviva Pharmaceuticals. Aytu BioPharma is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$1.85	N/A
Aytu BioPharma	$57.57M	0.39	-$14.25M	-$1.66	N/A

Reviva Pharmaceuticals currently has a consensus price target of $53.33, indicating a potential upside of 10,357.52%. Aytu BioPharma has a consensus price target of $14.50, indicating a potential upside of 610.78%. Given Reviva Pharmaceuticals' higher probable upside, research analysts clearly believe Reviva Pharmaceuticals is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Reviva Pharmaceuticals has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market.

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 8.9% of Reviva Pharmaceuticals shares are held by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Reviva Pharmaceuticals has a net margin of 0.00% compared to Aytu BioPharma's net margin of -24.76%. Aytu BioPharma's return on equity of -56.54% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
Aytu BioPharma	-24.76%	-56.54%	-13.14%

In the previous week, Aytu BioPharma had 8 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 10 mentions for Aytu BioPharma and 2 mentions for Reviva Pharmaceuticals. Aytu BioPharma's average media sentiment score of 0.77 beat Reviva Pharmaceuticals' score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Reviva Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aytu BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aytu BioPharma beats Reviva Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Reviva Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVPH vs. The Competition

Export

Metric	Reviva Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.69M	$12.22B	$7.14B	$13.26B
Dividend Yield	N/A	2.65%	2.53%	17.34%
P/E Ratio	-0.28	799.72	274.32	26.20
Price / Sales	N/A	756.29	618.16	93.09
Price / Cash	N/A	15.08	27.22	34.70
Price / Book	0.34	10.68	11.23	6.40
Net Income	-$19.86M	$2.83B	$3.49B	$381.07M
7 Day Performance	6.67%	-2.20%	-1.68%	-0.65%
1 Month Performance	-3.77%	-6.55%	-5.97%	-4.51%
1 Year Performance	-95.32%	-4.52%	8.11%	1.82%

Reviva Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVPH Reviva Pharmaceuticals	1.7475 of 5 stars	$0.51 +2.0%	$53.33 +10,357.5%	-95.4%	$6.69M	N/A	N/A	5	Gap Down
BGM BGM Group	0.9161 of 5 stars	$0.27 +10.7%	N/A	-96.7%	$26.25M	$37.92M	N/A	471
VIRI Virios Therapeutics	N/A	$1.36 -4.9%	N/A	-77.2%	$26.19M	N/A	N/A	5
PLRZ Polyrizon	1.2859 of 5 stars	$10.75 +3.7%	N/A	+46.9%	$25.78M	N/A	N/A	1	News Coverage Earnings Report
QNTM Quantum Biopharma	1.8828 of 5 stars	$3.93 -0.8%	$8.00 +103.7%	-81.4%	$25.13M	N/A	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RVPH) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Reviva Pharmaceuticals (RVPH) Competitors

RVPH vs. BGM, VIRI, PLRZ, QNTM, and AYTU

How does Reviva Pharmaceuticals compare to BGM Group?

Summary

How does Reviva Pharmaceuticals compare to Virios Therapeutics?

Summary

How does Reviva Pharmaceuticals compare to Polyrizon?

Summary

How does Reviva Pharmaceuticals compare to Quantum Biopharma?

Summary

How does Reviva Pharmaceuticals compare to Aytu BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH vs. The Competition

Reviva Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Reviva Pharmaceuticals (RVPH) Competitors

RVPH vs. BGM, VIRI, PLRZ, QNTM, and AYTU

How does Reviva Pharmaceuticals compare to BGM Group?

Does the media favor BGM or RVPH?

Which has preferable valuation and earnings, BGM or RVPH?

Do analysts rate BGM or RVPH?

Do insiders and institutionals believe in BGM or RVPH?

Which has more risk and volatility, BGM or RVPH?

Is BGM or RVPH more profitable?

Summary

How does Reviva Pharmaceuticals compare to Virios Therapeutics?

Is RVPH or VIRI more profitable?

Does the media prefer RVPH or VIRI?

Do analysts recommend RVPH or VIRI?

Which has more risk & volatility, RVPH or VIRI?

Do insiders & institutionals believe in RVPH or VIRI?

Which has preferable earnings & valuation, RVPH or VIRI?

Summary

How does Reviva Pharmaceuticals compare to Polyrizon?

Is PLRZ or RVPH more profitable?

Does the media favor PLRZ or RVPH?

Which has higher valuation and earnings, PLRZ or RVPH?

Do analysts recommend PLRZ or RVPH?

Which has more risk & volatility, PLRZ or RVPH?

Do institutionals and insiders believe in PLRZ or RVPH?

Summary

How does Reviva Pharmaceuticals compare to Quantum Biopharma?

Which has more risk & volatility, QNTM or RVPH?

Do insiders and institutionals hold more shares of QNTM or RVPH?

Is QNTM or RVPH more profitable?

Do analysts prefer QNTM or RVPH?

Does the media prefer QNTM or RVPH?

Which has stronger earnings and valuation, QNTM or RVPH?

Summary

How does Reviva Pharmaceuticals compare to Aytu BioPharma?

Which has stronger earnings and valuation, RVPH or AYTU?

Do analysts rate RVPH or AYTU?

Which has more volatility and risk, RVPH or AYTU?

Do institutionals & insiders believe in RVPH or AYTU?

Is RVPH or AYTU more profitable?

Does the media refer more to RVPH or AYTU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH vs. The Competition

Reviva Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools